<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002548</url>
  </required_header>
  <id_info>
    <org_study_id>SWOG-9321</org_study_id>
    <secondary_id>SWOG-9321</secondary_id>
    <secondary_id>CLB-9312</secondary_id>
    <secondary_id>E-S9321</secondary_id>
    <secondary_id>INT-0141</secondary_id>
    <secondary_id>U10CA032102</secondary_id>
    <nct_id>NCT00002548</nct_id>
  </id_info>
  <brief_title>SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma</brief_title>
  <official_title>Standard Dose Versus Myeloablative Therapy for Previously Untreated Symptomatic Multiple Myeloma, A Phase III Intergroup Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer and Leukemia Group B</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer
      cells. Combining chemotherapy and radiation therapy with peripheral stem cell transplantation
      may allow the doctor to give higher doses of chemotherapy and radiation therapy and kill more
      cancer cells. It is not yet known which treatment regimen is more effective for multiple
      myeloma.

      PURPOSE: Randomized phase III trial to compare the effectiveness of melphalan, total-body
      irradiation, and peripheral stem cell transplantation with that of combination chemotherapy
      in treating patients who have previously untreated multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare tumor cytoreduction achieved with VBMCP
           (vincristine/carmustine/melphalan/cyclophosphamide/prednisone) vs myeloablative
           melphalan (L-PAM) and total-body irradiation (TBI) with peripheral blood stem cell
           (PBSC) rescue in symptomatic myeloma patients with stable or responding disease after
           induction therapy with VAD (vincristine/doxorubicin/dexamethasone) followed by high dose
           cyclophosphamide plus filgrastim (G-CSF).

        -  Compare the efficacy of interferon alfa vs no maintenance therapy in those patients
           achieving at least 75% cytoreduction to either VBMCP or myeloablative therapy with PBSC
           rescue.

        -  Assess allogeneic bone marrow transplantation following the same myeloablative regimen
           of L-PAM/TBI in patients up to age 55 with an HLA-compatible, MLC-nonreactive donor. (As
           of 8/1/97, permanent partial closure)

        -  Determine whether myeloablative therapy with PBSC rescue can extend the duration of
           survival by 33% compared to results from standard dose VBMCP.

        -  Evaluate the toxic effects and possible long term side effects, including development of
           myelodysplastic disease and/or acute myeloblastic leukemia, associated with these
           treatments.

      OUTLINE: This is a randomized study. Patients are registered at 5 different points, with
      stratification occurring at some of these registrations.

        -  Registration I: Induction I

        -  Registration II: Induction II. Patients are stratified according to stage of disease
           (I/II vs IIIA vs IIIB), beta-2 microglobulin at diagnosis (less than 6 micrograms/mL vs
           at least 6 micrograms/mL), and response to Induction I (75-100% regression vs 50-74%
           regression vs less than 50% regression vs not applicable).

        -  Registration III: Patients are randomized to allogeneic bone marrow transplant (BMT)
           (this arm closed as of 8/1/97) or autologous BMT. Patients are stratified according to
           treatment received (high dose cyclophosphamide (CTX) and peripheral blood stem cells
           (PBSC) prior to autologous BMT vs prior to chemotherapy) and beta-2 microglobulin at
           this registration (less than 2 micrograms/mL vs no greater than 3 micrograms/mL vs
           unknown).

        -  Registration IV: Patients are randomized to maintenance therapy or no further therapy.
           Those patients who are randomized to maintenance therapy are stratified according to
           treatment (autologous BMT vs chemotherapy vs chemotherapy followed by autologous BMT)
           and response to treatment (75-99% regression vs complete response).

        -  Registration V: Patients receive autologous BMT as in registration III. Patients are
           stratified according to prior best response (50% or better vs less than 50% vs not
           applicable), duration of chemotherapy (at least 6 months vs less than 6 months), and
           progression after therapy (chemotherapy vs interferon alfa vs observation).

        -  Induction I: Patients receive vincristine IV and doxorubicin IV by continuous infusion
           on days 1-4 and dexamethasone IV or orally on days 1-4, 9-12, and 17-20. Treatment
           repeats every 5 weeks for up to 4 courses. Patients with progressive disease after 2
           courses proceed to PBSC stimulation/harvest.

      Allogeneic BMT arm is permanently closed as of 8/1/97.

        -  Autologous BMT: Therapy begins 4-8 weeks following high dose cyclophosphamide. Patients
           receive melphalan IV over 1 hour on day -5 and total body irradiation twice a day on
           days -4 to -1. PBSC are reinfused on day 0. G-CSF SQ is administered beginning on day 1
           until blood counts recover.

        -  Chemotherapy: Patients receive vincristine IV, carmustine IV, and cyclophosphamide IV on
           day 1, oral melphalan on days 1-4, and oral prednisone on days 1-7. Treatment repeats
           every 5 weeks for at least 12 months.

      Patients who have at least a 75% response to autologous BMT or chemotherapy are randomized to
      maintenance vs no further therapy. Patients who progress on chemotherapy proceed to
      autologous BMT (registration V).

        -  Maintenance therapy: Therapy begins between 5 and 12 weeks after PBSC rescue. Patients
           receive interferon alfa SQ three times a week. Treatment continues for 4 years in the
           absence of disease progression or unacceptable toxicity.

      Patients who progress on chemotherapy undergo an autologous BMT within 8 weeks after the last
      course of chemotherapy.

      Patients who are randomized to receive no further therapy are observed for 1 year.

      PROJECTED ACCRUAL: A total of 500 patients will be randomized over about 4 years to
      autologous transplantation vs chemotherapy as follows: about 250 patients/year will be
      accrued for induction of whom 200 will achieve at least stable disease, 125 will be
      randomized, and 15 will have a suitable donor for allogeneic transplant (as of 8/1/97,
      allogeneic arm of study is closed). Approximately 300 patients are expected to be randomized
      to maintenance vs no further therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1994</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival</measure>
    <time_frame>3 years from randomization</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">899</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>HDCTX and PBSC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose chemotherapy with peripheral blood stem cells
High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20
2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection
Chemo: vincristine 1.2 mg/m2 IV D1, BCNU 20 mg/m2 IV D1, melphalan 8 mg/m2 PO D1-4, cyclophosphamide 400 mg/m2 IV D1, prednisone 40 mg/m2 PO D1-7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HDCTX with PBSC and Autologous BMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant
High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant
High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20
2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection
Auto Trans: Mel 140mg/m2 IV D-5; TBI 150cGy D-4, -3, -2, -1; infusion D0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HDCTX with PBSC and interferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose chemotherapy with peripheral blood stem cells and interferon
Experimental: HDCTX with PBSC and interferon High dose chemotherapy with peripheral blood stem cells and interferon
High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20
2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection
Chemo: vincristine 1.2 mg/m2 IV D1, BCNU 20 mg/m2 IV D1, melphalan 8 mg/m2 PO D1-4, cyclophosphamide 400 mg/m2 IV D1, prednisone 40 mg/m2 PO D1-7
IFN: IFN 3 million units/m2 MWF SQ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HDCTX with PBSC and transplant plus IFN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant plus alpha interferon
Experimental: HDCTX with PBSC and transplant plus IFN High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant plus alpha interferon
High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20
2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection
Trans: Mel 140mg/m2 IV D-5; TBI 150cGy D-4, -3, -2, -1; infusion D0
IFN: 3 million units/m2 MWF SQ</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
    <description>3 million units/m2 SQ Monday-Wednesday
-Friday (3 times a week)</description>
    <arm_group_label>HDCTX with PBSC and interferon</arm_group_label>
    <arm_group_label>HDCTX with PBSC and transplant plus IFN</arm_group_label>
    <other_name>IFN, alpha interferon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
    <description>20 mg/m2 I.V. day 1 q 35 days</description>
    <arm_group_label>HDCTX with PBSC and Autologous BMT</arm_group_label>
    <arm_group_label>HDCTX with PBSC and transplant plus IFN</arm_group_label>
    <other_name>BCNU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)</description>
    <arm_group_label>HDCTX with PBSC and Autologous BMT</arm_group_label>
    <arm_group_label>HDCTX with PBSC and transplant plus IFN</arm_group_label>
    <other_name>cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>40 mg/day PO or IVPB days 1-4, 9-12, 17-20 q 5 weeks</description>
    <arm_group_label>HDCTX with PBSC and Autologous BMT</arm_group_label>
    <arm_group_label>HDCTX with PBSC and transplant plus IFN</arm_group_label>
    <other_name>steroid, decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>10 mg/m2/day continuous 1 - 4 q 5 weeks</description>
    <arm_group_label>HDCTX and PBSC</arm_group_label>
    <arm_group_label>HDCTX with PBSC and Autologous BMT</arm_group_label>
    <arm_group_label>HDCTX with PBSC and interferon</arm_group_label>
    <arm_group_label>HDCTX with PBSC and transplant plus IFN</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>140 mg/m2 is given IV within 30 minutes of constitution on Day -5</description>
    <arm_group_label>HDCTX and PBSC</arm_group_label>
    <arm_group_label>HDCTX with PBSC and Autologous BMT</arm_group_label>
    <arm_group_label>HDCTX with PBSC and interferon</arm_group_label>
    <arm_group_label>HDCTX with PBSC and transplant plus IFN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>40 mg/m2 PO days 1-7 q 35 days</description>
    <arm_group_label>HDCTX and PBSC</arm_group_label>
    <arm_group_label>HDCTX with PBSC and Autologous BMT</arm_group_label>
    <arm_group_label>HDCTX with PBSC and interferon</arm_group_label>
    <arm_group_label>HDCTX with PBSC and transplant plus IFN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>0.5 mg/day continuous 1 - 4 q 5 weeks</description>
    <arm_group_label>HDCTX and PBSC</arm_group_label>
    <arm_group_label>HDCTX with PBSC and interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
    <description>day 0</description>
    <arm_group_label>HDCTX with PBSC and Autologous BMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
    <description>day 0</description>
    <arm_group_label>HDCTX with PBSC and Autologous BMT</arm_group_label>
    <arm_group_label>HDCTX with PBSC and transplant plus IFN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>day 0</description>
    <arm_group_label>HDCTX and PBSC</arm_group_label>
    <arm_group_label>HDCTX with PBSC and Autologous BMT</arm_group_label>
    <arm_group_label>HDCTX with PBSC and interferon</arm_group_label>
    <arm_group_label>HDCTX with PBSC and transplant plus IFN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>administered in fractionated doses of 150 cGy, 6 - 10 hours apart bid, on Days -4, -3, -2, and -1 (Total 1,200 cGy)</description>
    <arm_group_label>HDCTX with PBSC and Autologous BMT</arm_group_label>
    <arm_group_label>HDCTX with PBSC and transplant plus IFN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Newly diagnosed, active multiple myeloma of any stage requiring treatment

               -  Smoldering myeloma (Durie-Salmon stage I) must have a 25% or greater increase in
                  M component levels and/or Bence-Jones protein excretion or development of
                  symptoms

          -  Quantifiable M component of IgG, IgA, IgD, IgE, and/or urinary kappa or lambda light
             chain (Bence-Jones protein) excretion required

               -  Plasmacytosis of at least 30% allowed for non-secretory disease or secretory
                  disease without quantifiable protein

               -  IgM peaks excluded

          -  Evaluation of siblings as potential allogeneic bone marrow transplant donors required
             for patients 55 years of age and younger (As of 8/1/97, permanently closed)

               -  HLA followed by DR and MLC testing required

          -  Renal failure, even on dialysis, eligible provided:

               -  Cause is attributed to myeloma (Bence-Jones protein or hypercalcemia)

               -  Duration does not exceed 2 months

          -  If medically appropriate, the following conditions should be treated prior to
             registration:

               -  Pathologic fractures

               -  Pneumonia at diagnosis

               -  Hyperviscosity with shortness of breath

        PATIENT CHARACTERISTICS:

        Age:

          -  70 and under

        Performance status:

          -  SWOG 0-2 (SWOG 3 or 4 based solely on bone pain allowed)

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  See Disease Characteristics

        Cardiovascular:

          -  Normal ejection fraction by ECHO or MUGA

          -  No myocardial infarction within 6 months

          -  No unstable angina

          -  No difficult to control congestive heart failure

          -  No uncontrolled hypertension

          -  No difficult to control arrhythmias

          -  No history of chronic cerebral vascular accident

        Pulmonary:

          -  No history of chronic obstructive or restrictive pulmonary disease

          -  Pulmonary function studies and DLCO at least 50% of predicted except for demonstrated
             myeloma involvement on bronchoscopy and/or open lung biopsy

        Other:

          -  No uncontrolled diabetes

          -  No significant comorbid medical condition

          -  No uncontrolled, life-threatening infection

          -  No prior malignancy within 5 years except adequately treated nonmelanoma skin cancer
             or carcinoma in situ of the cervix

          -  No prior malignancy treated with cytotoxic drugs used on this protocol

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy except local radiotherapy provided the following cumulative dose
             limits for prior dose plus potential TBI dose on protocol are not exceeded:

               -  Less than 5,000 cGy to bone

               -  Less than 4,000 cGy to mediastinum, heart, small bowel, brain, and spinal cord

               -  Less than 2,000 cGy to the liver

               -  Less than 1,500 cGy to the kidney and lungs

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Barlogie, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth C. Anderson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert A. Kyle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Scottsdale Oncology Program</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Colorado Cancer Research Program, Inc.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209-5031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Lakeside Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Evanston</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Illinois Oncology Research Association</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Indianapolis (Roudebush)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Iowa Oncology Research Association</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309-1016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Ochsner</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Medical Center Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Ann Arbor Regional</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kalamazoo</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-3731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Duluth</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Metro-Minnesota</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Comprehensive Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine's Kaplan Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Toledo Community Hospital Oncology Program</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623-3456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Geisinger Clinic and Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-2001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hahnemann University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102-1192</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-3489</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Marshfield Medical Research and Education Foundation</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Milwaukee (Zablocki)</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>van Ness BG, Ramos C, Kumar V, et al.: Analytical approaches for the BOAC SNP panel association with progression free survival in myeloma. [Abstract] Blood 112 (11): A-2715, 2008.</citation>
  </reference>
  <reference>
    <citation>Crowley JJ, McCoy J, LeBlanc M, et al.: Extreme regression: a statistical technique for finding good or poor prognostic groups, illustrated using myeloma patient data from Intergroup trial S9321. [Abstract] Blood 104 (11): A-5202, 2004.</citation>
  </reference>
  <reference>
    <citation>Greipp PR, Kumar S, Blood EA, et al.: A simple classification to identify poor-risk untreated myeloma. [Abstract] Blood 100 (11 Pt 1): A-2351, 598a, 2002.</citation>
  </reference>
  <reference>
    <citation>Tian E, Bumm K, Xiao Y, et al.: A protocol for triple color interphase FISH on archived bone marrow biopsies from myeloma prepared with precipitating fixatives. [Abstract] Blood 96 (11 pt 1): A-665, 155a, 2000.</citation>
  </reference>
  <reference>
    <citation>Rajkumar V, Leong T, Fonseca R, et al.: Bone marrow angiogenesis has prognostic value in multiple myeloma: an Eastern Cooperative Oncology Group study. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A68, 19a, 1999.</citation>
  </reference>
  <reference>
    <citation>Rimsza LM, Campbell K, Dalton WS, Salmon S, Willcox G, Grogan TM. The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma. Leuk Lymphoma. 1999 Jul;34(3-4):315-24.</citation>
    <PMID>10439368</PMID>
  </reference>
  <results_reference>
    <citation>Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006 Feb 20;24(6):929-36. Epub 2006 Jan 23. Erratum in: J Clin Oncol. 2006 Jun 10;24(17):2687. Moore, Dennis F Jr [added].</citation>
    <PMID>16432076</PMID>
  </results_reference>
  <results_reference>
    <citation>Van Ness BG, Crowley JC, Ramos C, et al.: SNP genotypes show association with common toxicities during both VAD induction and high dose melphalan with autologous transplant support in intergroup trial S9321 for myeloma: from the Bank on a Cure. [Abstract] Blood 106 (11): A-3488, 2005.</citation>
  </results_reference>
  <results_reference>
    <citation>Crowley J, Fonseca R, Greipp P, et al.: Comparable survival in newly diagnosed multiple myeloma (MM) after VAD induction with high dose therapy using melphalan 140mg/m2 + TBI 12 Gy (MEL+TBI) versus standard therapy with VBMCP and no benefit from interferon (IFN) maintenance: final clinical results of intergroup trial S9321 in the context of IFM 90 and MRC VII trials. [Abstract] Blood 104 (11): A-539, 2004.</citation>
  </results_reference>
  <results_reference>
    <citation>Santana-Davila R, Crowley J, Durie B, et al.: Genetic polymorphisms associated with clinical outcome in the intergroup trial S9321, comparing high dose therapy with standard dose therapy for myelomaon, on behalf of ECOG, SWOG, CALGB, and the Bank on a Cure. [Abstract] Blood 104 (11): A-1495, 2004.</citation>
  </results_reference>
  <results_reference>
    <citation>Lee CK, McCoy J, Anderson KC, et al.: Long-term follow-up of previously untreated symptomatic myeloma patients treated with myeloablative therapy and sibling-matched allogeneic transplantation of the SWOG study 9321. [Abstract] Blood 100 (11 pt 1): A-1644, 2002.</citation>
  </results_reference>
  <results_reference>
    <citation>Greipp PR, Jacobson JL, Crowley JJ, et al.: BETA 2 microglobulin (beta 2M) and plasma cell labeling index (PCLI) constitute a strong prognostic index in the SWOG intergroup transplant trial S9321: observations on gender and age. [Abstract] Blood 96 (11 pt 1): A-653, 152a, 2000.</citation>
  </results_reference>
  <results_reference>
    <citation>Desika R, Salmon S, Anderson K, et al.: Planned melphalan-total body irradiation (MEL-TBI) - based allogeneic transplantation for multiple myeloma (MM) up to age 55: an intergroup experience (CALGB, ECOG and SWOG) under the auspices of the Southwest Oncology Group (SWOG 9321). [Abstract] Blood 94 (10 Pt 1): A-1546, 346a, 1999.</citation>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2003</study_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

